中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
20期
156-157
,共2页
大肠癌%化疗%免疫功能%淋巴细胞亚群%变化
大腸癌%化療%免疫功能%淋巴細胞亞群%變化
대장암%화료%면역공능%림파세포아군%변화
Colorectal cancer%Chemotherapy%Immune function%Lymphocyte subsets%Change
目的：对大肠癌患者化疗前后淋巴细胞亚群变化进行分析。方法抽取大肠癌患者68例，对其采取三标荧光抗体法展开化疗前后外周血21项淋巴细胞亚型标记，经流式细胞仪对淋巴细胞亚群的变化进行检测。结果化疗后，大肠癌患者外周血CD3+、CD3+CD8+、CD29+、CD4+CD29+、CD4+CD25+细胞在淋巴细胞中所占百分比较化疗前升高（P<0.05），而CD19+、人白细胞DR抗原（HLA-DR）细胞+所占百分比则较化疗前降低（P<0.05）。结论化疗能够使大肠癌患者体液免疫功能降低。
目的：對大腸癌患者化療前後淋巴細胞亞群變化進行分析。方法抽取大腸癌患者68例，對其採取三標熒光抗體法展開化療前後外週血21項淋巴細胞亞型標記，經流式細胞儀對淋巴細胞亞群的變化進行檢測。結果化療後，大腸癌患者外週血CD3+、CD3+CD8+、CD29+、CD4+CD29+、CD4+CD25+細胞在淋巴細胞中所佔百分比較化療前升高（P<0.05），而CD19+、人白細胞DR抗原（HLA-DR）細胞+所佔百分比則較化療前降低（P<0.05）。結論化療能夠使大腸癌患者體液免疫功能降低。
목적：대대장암환자화료전후림파세포아군변화진행분석。방법추취대장암환자68례，대기채취삼표형광항체법전개화료전후외주혈21항림파세포아형표기，경류식세포의대림파세포아군적변화진행검측。결과화료후，대장암환자외주혈CD3+、CD3+CD8+、CD29+、CD4+CD29+、CD4+CD25+세포재림파세포중소점백분비교화료전승고（P<0.05），이CD19+、인백세포DR항원（HLA-DR）세포+소점백분비칙교화료전강저（P<0.05）。결론화료능구사대장암환자체액면역공능강저。
Objective To analyze the changes of lymphocyte subsets in patients with colorectal cancer before and after chemotherapy.MethodsThe selected patients with colorectal carcinoma in 68 cases,the take three standard fluorescent antibody method before and after chemotherapy in peripheral blood of 21 lymphocyte subtype markers and by flow cytometry was used to detect the changes of lymphocyte subsets.Results After chemotherapy,in patients with colorectal cancer week blood CD3+,CD3+CD8+,CD29+,CD4+CD29+,CD4+CD25+T cels in lymphocytes accounted for percent of chemotherapy before increased(P< 0.05),and CD19+,human leukocyte antigen DR(HLA-DR)cels+ percentage than before chemotherapy reduced(P< 0.05).Conclusion Chemotherapy can reduce the humoral immune function in patients with colorectal cancer.
